- Product Details
Keywords
- cisatracurium besylate
- 96946-42-8
- C65H82N2O18S2
Quick Details
- ProName: cisatracurium besylate
- CasNo: 96946-42-8
- Molecular Formula: C65H82N2O18S2
- Appearance: White powder
- Application: Cisatracurium besylate is the latest g...
- DeliveryTime: 2 weeks after confirming the order
- PackAge: 25kg/bag/drum,according to customer's ...
- Port: QINGDAO/SHANGHAI/SHENZHEN/HONGKONG
- ProductionCapacity: 1000 Kilogram/Month
- Purity: ≥98.5%
- Storage: Store in a tightly closed container. S...
- Transportation: By air/by sea/ by express
- LimitNum: 10 Gram
Superiority
Henan Wising Chem Co., Ltd is a national high-tech enterprise with a passion for selling and an emphasis on customer care.
We are committed to providing quality chemical products that help us become one of the most reputable, reliable and leading chemical products suppliers in the domestic and global markets.
We purpose to bring our value clients the best quality products, the most competitive prices, the shortest delivery and the best service.
Our customers include BASF, Bayer, Merck, AstraZeneca, Sun Pharma, Shanghai Pharmaceuticals, MSN Laboratories, Unither Pharmaceuticals, Cadila Healthcare, and Abbott, Amgen in the US.
Wising Chem is a reliable distributor in domestic and global markets, we own an excellent reserch team based on Zhengzhou University, Shanghai Medical College of Fudan University and Henan University of Animal Husbandry&Economy, we focus on Pharmaceutical intermediates, API, rare chemiclas, and fine chemicals.
Details
Cisatracurium besylate is the latest generation of myorelaxant. Compared with the main clinical myorelaxant anesthetics, it has the characteristics of non-hepatic and non-renal metabolism and cardiovascular stability, and its myorelaxant effect is three times stronger than that of atracurium, without cardiovascular side effects. Cisatracurium is mainly used in general anesthesia and can be widely used in tracheal intubation, hepatic and renal dysfunction, cardiovascular surgery and geriatric and pediatric patients. Since it was first marketed in the UK in 1996, it has gradually replaced vecuronium bromide and atracurium as the mainstream of clinical inotropic agents abroad.